• Hillcrest announces AGM results; all seven members of Board of Directors are re-elected while new board chair David Farrell is appointed
• Company exits fossil-fuel business and completes transition to clean tech market where it continues to develop inverter technology empowering next generation of more efficient and powerful electric vehicles
• Hillcrest reaches key milestone as it completes proof of concept testing of its inverter technology, with the commercial prototype soon to be available in Q4 2022

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a Canadian cleantech company developing technologies for innovative electrical solutions such as powertrains and grid-connected renewable energy systems, has announced the voting results from its Annual General Meeting held Wednesday, June 29, 2022. The Board of Directors and Management received extraordinary support from shareholders, who overwhelmingly voted in favor of the proposed items, including the composition of the Company’s leadership. Hillcrest also announced the completion of its transition toward clean energy technologies by formally announcing the end of its oilfield activities (https://ibn.fm/pRIUD). All seven of Hillcrest’s Board members have been re-elected, with a new Chair, David Farrell, heading the team as the previous Executive Chair, Michael Krzus, stepped down after having served for the past seven years. Mr. Farrell, who has also served on the Hillcrest Board for the past year, brings to the team more than 25 years of corporate and investment banking experience, working with a number of global junior and mid-tier companies through their major growth stages. As part of its commitment to environmentally responsible operations, Hillcrest recently decided to change the Company’s direction towards the exit from the fossil fuel business and focus its efforts on commercializing clean technologies. The Company is confident that Mr. Farrell is well-positioned to lead Hillcrest as it evolves into a mature, clean energy technology company. With ambitious plans for its clean tech future, Hillcrest also solidified its technical team with Ronald Rebeiro, an electrical machine design and motor drives expert who holds a Ph.D. in electrical and electronics engineering. Mr. Rebeiro is expected to focus on engineering project management and testing activities at the Company’s Vancouver tech development lab (https://ibn.fm/4twvs). Hillcrest continues to make strides in its new clean tech market, where it concentrates on offering a flexible, single-inverter architecture applicable at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of electric vehicles to providing full-cycle efficiency and performance improvements. The Company has completed proof of concept testing of its EV traction inverter, demonstrating a reduction in switching losses of +90% compared to conventional, hard-switched inverters employed in many electrical vehicles today. Work is currently underway on the commercial prototype for its EV traction inverter, expected to be available to customers in Q4 2022. The new test signifies a key milestone in the commercialization testing protocol as it examined specifically the efficiencies enabled by Hillcrest’s soft-switching technology. Due to the trade-off between the optimal switching behavior and acceptable thermal losses, currently deployed electric motors operate within a switching frequency range of 8kHz to 16kHz. Hillcrest’s high-efficiency inverter could be a game changer for next generation EVs as it is able to soft-switch at much higher frequencies without causing additional losses. As a result, the new technology could potentially enable motor manufacturers to take advantage of new motor concepts beyond the scope currently available. These potential efficiencies, previously unimaginable, could allow higher power density, lower cost and weight and better power quality and EV performance in the future. More details are available in the recent technical whitepaper published on the Hillcrest website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months
• The pivotal study was designed with four primary objectives
• Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD

Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule,” said Cybin CO Doug Drysdale. “Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.” The Phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary. The study was designed with four primary objectives: to evaluate the safety of increasing doses of a single-dose, continuous DMT infusion over 90 minutes; to characterize the PK of a single-dose DMT administered continuously over 90 minutes; to characterize the PD of a single-dose DMT administered continuously over 90 minutes; and to establish the minimum DMT dose required to produce a psychedelic effect. The adaptive, randomized, double-blind, placebo-controlled, single-ascending-dose study produced notable results. According to the study, inhaled CYB004 showed an estimated 2,000% improved bioavailability compared with orally administered DMT and a 41% improved bioavailability compared with inhaled DMT. In addition, Cybin’s CYB004 demonstrated an approximately 300% longer duration of effect when compared with IV DMT as well as a rapid onset of effect and low variability equivalent to IV DMT. Cybin plans to evaluate the results from this study, along with other key data, to identify the next steps forward for its proprietary substance. “The most precious commodity in drug development is time, and acquiring this robust Phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months,” said Drysdale. “The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule. This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class.” CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February 2022. The proprietary substance has the potential to effectively treat anxiety disorders, including generalized anxiety disorder (“GAD”) and social anxiety disorder (“SAD”). In its natural form, DMT is rapidly metabolized in the body and is not orally bioavailable. However, preclinical studies, including the CYB004-E study, have demonstrated that CYB004 has the potential to overcome these issues and provide increased oral and pulmonary bioavailability, faster onset with lower doses, low interpatient variability, and better dose titration, with fewer side effects and longer-acting desensitization of the serotonergic receptors. Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• GMGI CEO says new P2P Esports offering coming “quite soon”
• Gaming operators have need for new products to grow market share
• New product overcomes challenges related to compliance in Esports gambling

If you’re paying attention to the sports betting market, you’re seeing companies big and small looking for edges to capture market share from competition in a fierce, albeit huge, marketplace. It’s tough to carve out profits when, in the words of Brian Goodman, CEO of Golden Matrix Group (NASDAQ: GMGI), “everyone [is] fishing in the same pond.” Companies must be differentiated, as is Golden Matrix, a provider of turnkey and white label gaming platforms, Esports technology, and gaming content that has notched 15 straight profitable quarters. As more and more U.S. states legalize online gambling, there is room for vertical growth for sportsbooks, daily fantasy sports (“DFS”), and casinos. However, operators need to continue to follow trends to get into the pockets of new players. Many of these players win and retention opportunities are centered on non-professional betters, women, and younger players that don’t seem to want to follow conventional betting modalities. That is leading to a race to establish a footprint in Esports gambling and peer-to-peer betting, amongst other things. These are some of the immediate blue-sky chances to juice revenue streams or get fledgling companies off the ground. Golden Matrix’s roots are in B2B (business-to-business) gambling, where its technology is used by over 500 casino operators serving 7+ million players. The Las Vegas-based company has recently branched out into B2C (business-to-consumer) offerings through the acquisition of 80% of UK-based skilled competition operator RKingsCompetitions Ltd. Golden Matrix was recently featured in financial media and data company Benzinga’s Esports Listmakers Series where Goodman spoke about the state of the industry and some of the challenges involved with Esports and betting on them. It’s not as simple as being a facilitator of two friends betting who has more kills in any specific Esports game. For one thing, gambling on smaller events in sports known for rapid player turnover mean greater opportunities for collusion. Plus, operators are responsible for ensuring all government regulations are followed regarding money transfer, bettor locations, and, amongst other things, the age of gamblers. In jurisdictions around the world, bettors must be a minimum of 18 years old, and 21 in many cases (or even 25, as in Portugal). This is critical with respect to Esports, where players and fans tend to be from younger demographics. The average competitor in Blizzard Entertainment’s Overwatch League is about 20 years old. Players aren’t much older in Activision’s Call of Duty League (average age is 22 years). In the Overwatch League, the average retirement age is just 23. Goodman says his company will be releasing a new peer-to-peer Esports betting platform “quite soon.” There have been some delays in launching the product even though it is in a Beta testing stage as we are waiting for our Mexican facing casino to be launched which should happen in the coming weeks. The Esports product allays concerns about following regulatory guidelines in the burgeoning market and is seen as a good fit for its existing user base and way to generate additional revenues in Mexico and in Asia-Pacific, Golden Matrix’s biggest market currently. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

The EV Charging Conference 2022 is a 2-day virtual event designed to optimize education, learning, and networking among industry professionals in the electric vehicle market and other participants. The highly specialized event focuses on addressing fundamentals at residential and commercial levels to drive ROI across the EV landscape and clean energy. Key Details

• The push for NetZero is creating a massive, untapped opportunity for EV Charging
• Reinvent your electric strategy for residential or commercial properties
• Thought leaders will share their knowledge, skills, and expertise to enable the successful integration of profitable EV charging into your organization

The forthcoming EV Charging Conference will be held in a completely virtual format on August 11-12, 2022, by the Global Strategic Management Institute (“GSMI”), a cutting-edge conference production firm focused on fostering disruptive innovation. This conference provides a world-class platform geared towards untapped knowledge sharing, networking with industry speakers, learning about emerging technologies and fresh incentive structures, fostering innovative, collaborative relationships, and adopting successful strategies to enable your organization to be at the frontline of innovation and drive profit margins.  Core attendees will include C-suite executives, senior leadership, and middle management from Operations, Business Development, and Fleet Operations in various allied sectors and verticals, including alternative fuels, energy technology, city and urban planning, OEMs, EV strategy, and municipalities to name a few. Why Should You Attend? The conference aims to offer deep insight to the EV and clean energy communities about the most relevant investment and development strategies in installation, technology, and the broader industry across residential and commercial opportunities. Participants will gain a perspective into the EV charging landscape that can be tailored to their business models. Participants will experience real-time presentations in the sessions rooms, where they can enter and exit at their convenience, chat with other participants and interact directly with speakers. The conference also supports Real-Time Networking, enabling attendees, speakers, and sponsors to engage through dedicated chat functions and build lasting relationships during designated networking breaks, at topic-specific tables and in group discussions. Participants can also schedule one-on-one 15-minute video meetings with any of the 500+ EV charging professionals in attendance, all via a single seamless virtual forum. The two-day conference will host a comprehensive roster of senior-level executive leaders offering a rich, diverse mix of perspectives and knowledge. Attendees will have access to interactive and comprehensive panel discussions on wide-ranging topics, including The Demand for Investors (Artificial Intelligence, ROI, Planning); EV Reliability, Maintenance, and Cellular Communications; Collaborating with Municipalities and States; Funding Site Improvements: Getting the Most out of Incentives and Grants; Leveraging Available Technologies: Values of Charging Management, Bidirectional Charging and More; Prioritizing EV Charging at the Commercial Level; How HOA and Multi-Dwelling Complex Owners Navigate EV Charging Stations; and Fleet Electrification. Keynote Panels will also be held on Day 1 and Day 2, on The Future of EV Charging with Ahmed Mousa, Lead Utility of the Future at PSEG, and Andrew Duvall, Transportation Behaviour Analyst, NREL, as well as The Challenges of EV Charging with Fabio Mantovani, VP of eMobility at NY Power Authority; Adriana Perez, Enterprise Growth Acceleration at WOOD PLC; and John Erdman, Head of Strategic Accounts at FreeWire Technologies, respectively. The event will provide participants access to solo presentations from industry veterans on topics such as “Start to Finish: Site Evaluation and Installation for Sustainable EV Charging”, and “Power Storage and Management of Buildings and Batteries.” The EV Charging Conference is a marquee, must-attend event that will officially launch an exciting EV Charging event series. The lead event this August will focus on the opportunities and challenges faced by residential and commercial decision-makers. This will be followed by the second event of the series on October 18-19, 2022, with the EV Charging Infrastructure Conference, also in an easy-to-access fully virtual mode. Discussants will concentrate on the scaling-up of infrastructure to meet future demand for EV charging facilities, and will play host to city and urban planners, officials from leading utilities, government organizations, and electrical contractors. In February 2023, the series will move to its third and final event, a fascinating in-person expo, showcasing the latest developments across six key tracks including charging infrastructure; hardware, and software technologies; connecting consumers; business strategies; funding, and investments; and OEM manufacturing. To register for the conference, click here. For information on group discounts, contact Jessica Vargas or call 619-597-7315. To speak at the conference, become a sponsor, or for general inquiries, click here.

• Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments
• The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military
• Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”)
• Medication for concussion treatment remains an unmet need and Odyssey is aiming to be a first-mover in the healthcare sector

The National Council on Aging sponsors its Falls Prevention Week timed, not ironically, during the fall of each year, using its national health campaign to combat the leading cause of fatal and non-fatal injuries among older adults. One message of the council’s awareness campaign is the importance of recognizing that after an old person is helped back up, the fall victim may be able to resume walking, but there is still a significant risk of worsening effects from a concussion-related head injury (https://ibn.fm/rRsst). While the potential harm of concussion injuries in youth sports and among professional athletes is gaining an increasing measure of attention, concussions in elderly fall patients is also a prominent concern, and active military personnel also continue evaluating potential new treatments for concussion injuries sustained on duty. Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is working to address unmet needs in concussion therapy, to help patients beyond the standard of care for pain management, rest, and monitoring. A proprietary device and synthetic medication combination developed by Odyssey Health is being tested for safety related to treating concussion patients in the initial moments after a mild injury, successfully completing all three cohorts in the company’s Phase I Single Ascending Dosing (“SAD”) clinical trial recently and advancing to a Multiple Ascending Dosing (“MAD”) stage in which volunteers will be treated once daily for five straight days. “We have a very unique new chemical entity intended to treat mild traumatic brain injury — the acute phase of a concussion,” CEO Michael Redmond said during an interview with The RedChip Money Report(R) last month. “It’s a small device. It essentially goes and delivers a powderized drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within five minutes. It spreads out throughout the brain within 30 minutes and reverses the effects of a concussion” (https://ibn.fm/sdVcJ). The SAD and MAD clinical trials work with healthy human volunteers to establish the safety of Odyssey Health’s technology, which previously completed preclinical lab animal testing successfully and is expected to advance to a Phase II/III design that will determine the efficacy of the company’s PRV-002 technology for concussed patients. Phase II trial sites are already being identified and the study’s design is being created, working with military board advisers while company officials report their early efforts to the FDA. “We are actively identifying and assisting with Phase II military trial site setup,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated in a July 12 news release about Odyssey’s progress (https://ibn.fm/VLE3Q). “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” A significant target of the therapy involves getting the drug across the blood-brain barrier to directly deal with the central nervous system consequences of a head injury. “I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device”, Safety Review Committee member Dallas Hack, MD, stated after analyzing the SAD trial. “If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, the drug will likely have less potential side effects.” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• MULN shares traded higher after Benzinga stated that the emerging EV manufacturer had reported higher-than-expected battery test results
• Data shows the company’s proprietary solid-state polymer batteries can deliver more than 600 miles of range on a full charge
• The company plans to include the new batteries in its second-generation Mullen FIVE EV Crossover

Mullen Automotive (NASDAQ: MULN) was featured in a recent Benzinga Brief. The short summary noted that the company, an emerging electric-vehicle manufacturer, had reported results of its solid-state polymer battery testing, which exceeded expectations (https://ibn.fm/XI6Fa). Noting that shares were trading higher after the news, Benzinga quoted David Michery, Mullen CEO and chair, as saying, “The battery has performed exceptionally well, and I’m pleased with the results from BIC [Battery Innovation Center] in Indiana.” “Testing results from BIC show the solid-state polymer cell, rated at 300 Ah and 3.7 volts, tested at 343.28 Ah at 4.2 volts, exceeding expectation, and is in line with test tolerance from previous EV Grid test results,” the brief continues. “The data supports solid-state polymer battery cell technology [that], when scaled to the vehicle pack level and at a 150-kilowatt hour equivalent, can deliver over 600 miles of range on a full charge for the Mullen FIVE EV Crossover.” While the company plans to continue to test additional parameters to characterize overall capabilities and performance, these positive results bode well for the Southern California–based company, which owns and partners with synergistic businesses that share the same goal: to create clean, scalable electric vehicles and energy solutions (https://ibn.fm/D8vYz). The company announced plans to include the new solid-state polymer batteries in its second-generation Mullen FIVE EV Crossover (https://ibn.fm/Br0nl). In addition to offering more than 600 miles of range, the batteries can deliver 300 miles of range after an 18-minute DC fast charge. “We’ve conducted successful testing and will begin pack-level development next,” said Michery, who called the future bright for the nascent EV company. Key to the company’s success are several partnerships the company has built recently, including with hofer powertrain, Comau, ARRK, Dürr and DSA Systems. These partners will help Mullen produce improved EV powertrain, engineering, manufacturing, vehicle production systems, and over-the-air (“OTA”) and vehicle system diagnostics. “[Mullen] expects these strategic developments to play a crucial role in bringing the FIVE to market with the latest technology and in the shortest amount of time,” the company stated. The Mullen FIVE RS is a high-performance EV featuring close to 1,100 horsepower, 0 to 60 mph in only 1.95 seconds, and a top speed of almost 200 miles per hour (https://ibn.fm/KaCIj). The vehicle was awarded Top Zero Emission SUV as part of the ZEVA Awards at the Los Angeles International Auto Show in November 2021, where it debuted. For more information about the company, visit www.MullenUSA.com. NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

• Fossil fuels still account for about 80% of primary energy worldwide. They are responsible, on a per capita basis, for 63,130kWh of energy in the United States, with renewables onlyaccounting for 8,266 kWh
• The United States, prior to the recent ban, had 8% of its total petroleum imports (including crude oil) coming from Russia, a reliance that has now resulted in significant increases in gasoline and diesel prices
• Correlate, through its distributed clean energy solutions, is addressing these issues, helping to bring society closer to significantly less dependence on the national grid and more on green energy sources
• The company is capitalizing on the momentum of growing wind, solar, and even geothermal power production, to grow its market share, strengthen its brand equity, and diversify its product offering
• By providing energy programs for commercial property portfolios that require no upfront capital on the part of the customer, Correlate continues to build its appeal to potential clients, laying down a template that can be easily replicated and implemented in various sectors

Energy security and affordability have become increasingly critical factors for nations around the world. The Russia-Ukraine issue has pointed out how overreliance on specific energy supplies can be detrimental to national economies, and how bad the situation could get if geopolitical and other problems were to accelerate. Fossil fuels still account for about 80% of primary energy worldwide. The main source is oil, followed by coal, and it is further projected that this will continue to be the case for a long time. The United States, for instance, uses 63,130kWh of energy, per capita, from fossil fuels, with renewables only accounting for 8,266 kWh. Similar disparities are found in other countries, including, but not limited to, Canada, China, Japan, Australia, and the UK (https://ibn.fm/XxMAZ). This overreliance on fossil fuels presents international supply chain risks and challenges, affected by unexpected changes in linkages between energy markets. The U.S., prior to the recently imposed ban, had 8% of its total petroleum imports (including crude oil) coming from Russia. With the ongoing issue in Ukraine, this reliance and associated ban has caused issues with supply, ultimately resulting in a significant jump in gasoline and diesel prices (https://ibn.fm/cjiVv). Many other countries, of course, face the challenge of considerably more dependence. Correlate Infrastructure Partners (OTCQB: CIPI), a company offering a complete suite of proprietary clean energy assessment solutions for the commercial real estate industry, is committed to bringing society closer to less dependence on the national grid and, by extension, fossil fuels, to focus demand more on green energy sources. With its distributed clean energy solutions, the company believes that it can help mitigate the effects of climate change while at the same time ensuring that businesses, both big and small, have access to clean and reliable energy. A report published by Frontier Group and Environment America Research and Policy Center, noted that between 2011 and 2020, the proportion of electricity generated from wind and solar in the U.S. increased by about four times. More specifically, the study noted that wind, solar, and geothermal power production grew yearly by 15%, which by 2035 could meet the country’s electricity demand (https://ibn.fm/JgD9Y). Correlate looks to make the most out of growing consumer realization of the overreliance on fossil fuels, to build its customer numbers given its unique product offering, and to thus grow its market share, strengthen its brand equity, diversify its product offerings, and create value for its shareholders. So far, Correlate and its subsidiary, Solar Site Design, have an opportunity pipeline of over $100 million in commercial products, with over $20 million in awarded backlog. With more corporations realizing the benefits associated with alternative energy sources, specifically solar power, Correlate is confident that its opportunity pipeline will continue to grow, as will its customer base. By providing energy programs for commercial property portfolios requiring no upfront capital, Correlate is appealing to more potential clients while continually reducing the barrier of entry, encouraging a much-needed energy transition. The company understands its clients’ hurdles and seeks to address them to reduce demand dependence on fossil fuels and to increase the uptake of greener, more sustainable energy alternatives. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The rice production industry is under an imminent threat due to increased demand and reduced crop yields
• With Thailand, the Philippines, and China all facing problems in rice production, a lot rides on the success of India’s rice crops, despite the uncertainty of monsoon and harvest season
• FuelPositive Corp. is currently developing proprietary green ammonia technology driving for on-site fertilizer production and zero carbon emissions

The rice production industry faces multiple imminent threats worldwide, including rising fertilizer costs, climate change, and increased demand when crop yields seem to be declining. These threats pose a potential risk to food security and the efforts being made to contain inflation. Countries such as Thailand, China, India, and the Philippines, are already dealing with mounting concerns, due to the lower crop yields, climate change, invasion of pests, and the rising cost of crop nutrients. Most of the world’s rice is grown, eaten, and exported from Asia, making political stability in the region crucial to production efforts (https://ibn.fm/vQaoa). With the current status of the contributing countries, much is riding on India’s rice crop, which ships approximately 40% of the world’s exports in rice. Although India has limited wheat crops, the rice exports are helping ease the reduction in supply within the region. Should the wheat harvest be limited more due to the monsoon rains necessary for harvest season, it is possible that rice will be needed to supplement for food and livestock feed. According to Vice President and researcher V. Subramanian of The Rice Trader, “Global supply is at risk, but for now, we still have massive Indian availability that is reining in prices. Looking at the current situation, India is acting as an anchor for prices with its large exports.” The high prices for fertilizer and the inherent presence of climate change are driving factors for FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) message that fossil fuels don’t only damage the climate, but make the world economically vulnerable. FuelPositive is a growth-stage company focused on partnership and acquisition opportunities for energy efficiency and sustainability technologies. The company’s emphasis on economic vulnerability and climate change can be supported through the AR6 Synthesis Report (https://ibn.fm/tSc8e). Carbon emissions are the leading cause of climate change and global warming issues worldwide. The company’s Hydrogen-Ammonia Synthesizer technology provides the means necessary to store green hydrogen as green ammonia that is completely carbon-free. The hydrogen can be removed when needed for use in fuel cells and other applications based on pure hydrogen technologies. In the same way that ammonia is the perfect carrier for hydrogen, it is also the perfect carrier for nitrogen – the key component in fertilizers. FuelPositive has developed a containerized green ammonia production system relying on renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the two elements in a proprietary converter to form ammonia. The technology will allow farmers to economically produce the amount of ammonia needed to fertilize their crops on-site. In doing so it eliminates supply chain dependence, and stabilizes price while eliminating carbon emissions. The system can be scaled up or down, so farmers can produce the amount of fertilizer they need right on their farms and apply it when the timing is best. The first demonstration systems are being built to produce up to 300 kg/day, which amounts to 100 metric tonnes per year. FuelPositive expects to begin on-farm demonstration of its proprietary green ammonia production systems in fall 2022. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences
• Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control
• The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry
• Lexaria’s pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the pending start of an upcoming human nicotine study, NIC-H22-1. The company expects to evidence that processing purified nicotine with its patented DehydraTECH(TM) technology leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1 is a minimum 36-person human pharmacokinetic randomized, double-blind, cross-over study comparing DehydraTECH-nicotine pouch performance to existing brands currently on the market, including ON! and Zyn (https://ibn.fm/aFVPk). The study’s primary objective is the objective data collection from blood samples that will evidence Tmax, Cmax, and AUC. Other study objectives include extensive subjective evaluations related to complaints of throat burn, user experience, and more. The nicotine test article ingredient manufacturing and DehydraTECH processing have been completed, and the materials have been received by the third-party pouch manufacturing company for filling and packaging. This study’s next two major steps will be Independent Review Board approval and subsequent human dosing. Through a previous animal study NIC-A21-1, the company has already demonstrated that oral nicotine pouches using DehydraTECH technology were 10x to 20x faster at reaching peak delivery of nicotine to the bloodstream than the control. Lexaria is leveraging the oral nicotine pouch market, which is one of the fastest growing segments in the nicotine industry due in part to the US Food and Drug Administration’s note of “reduced risk health outcomes” (https://ibn.fm/SmOJi). The delivery method, specifically the white pouch format, avoids harmful lung outcomes experienced by smokers and vapers, only involving absorption primarily through the mouth’s buccal tissues through purified nicotine. In 2020, the global nicotine pouches market was valued at $2.33 billion and is expected to reach $21.84 billion by the end of 2027, growing at a CAGR of 30.7% during the forecast period. (https://ibn.fm/a8Wc0). On March 8, 2022, Lexaria announced that it had been granted a new patent, “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” The Australian patent expands Lexaria’s international intellectual property rights to apply DehydraTECH enhancement technology to most oral forms of nicotine, including pills, lozenges, capsules, pouches, gums, and sprays. Lexaria currently has 25 patents granted worldwide plus a 26th patent allowed in Japan. As detailed in Lexaria’s July 2022 Corporate Presentation, DehydraTECH is faster and more effective at delivering drugs into the bloodstream and brain tissues by increasing bioavailability, improving the speed of onset, reducing drug administrative costs, and masking the unwanted taste (https://ibn.fm/QptMW). The technology’s pipeline addresses serious unmet patient needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs. The current pipeline includes five studies currently in various stages, including animal PK/PD proof of concept for CBD for epilepsy and PDE5 inhibitors, human PK/PD proof of concept for oral nicotine (NIC-H22-1), and one study currently in the Investigational New Drug (“IND”) enabling study status, DehydraTECH-CBD for hypertension. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• NOWG signs MOU creating a strategic business partnership that will deliver value in India’s growing CSR market
• India has made CSR obligatory, requiring top companies that meet specific requirements to spend 2% of their normal net benefits on CSR initiatives annually
• The company announces the creation of the Nowigence Independent Growth Council

As evidence of its continued commitment to and progress toward becoming a gamechanger in the global data gathering and analysis space, Nowigence (OTCQB: NOWG) has made two key announcements. First, Nowigence signed a memorandum of understanding (“MOU”) with India-based EquiPPP Social Impact Technologies Ltd. (https://ibn.fm/NiyLD). Second, Nowigence has formed an independent growth council to advise, strategize and assist with delivery of its growth plan (https://ibn.fm/K4x3L). The MOU is designed to create a strategic business partnership in which EquiPPP will “act as a business development partner promoting Nowigence products in India and tailoring its core machine learning and natural language processing engine to develop information technology (‘IT’) and ITeSaaS (information technology enabled software as a service) products for corporate social responsibility (‘CSR’) activities, granting EquiPPP exclusive marketing rights for those CSR products in India,” Nowigence explained. EquiPPP is a publicly listed company that provides software services, is engaged in IT and ITeSaas, and offers a digital platform enabling various stakeholders to collaborate in implementing CSR projects. “We are happy to partner with EquiPPP to deliver value in the growing CSR market while benefiting society at large,” said Nowigence CEO Anoop Bhatia. “We are excited to jointly bring technology into the social programs space. Together, we hope to make a significant difference in our collective social responsibility, connecting donors and service organizations to improve the lives of the underprivileged.” India has made CSR obligatory, requiring top companies that meet specific requirements —annual revenues of more than $140 million, assets of more than $70 million or net benefits exceeding $700,000 — to spend 2% of their normal net benefits on CSR initiatives annually. This creates an ideal entry point for Nowigence, which has demonstrated expertise in artificial intelligence (“AI”), machine learning (“ML”) and natural language processing (“NLP”). As evidence of this expertise, NOWG has created Pluaris, a cutting-edge intelligent reader that mimics in real time the human process for knowledge assimilation while conducting a smart search. In addition, Nowigence announced the creation of the Nowigence Independent Growth Council, a group of industry experts with impressive experience in building successful tech companies. Members of the new council include Michael Connolly, Rohit Kumar, Tinsley Galyean, Girdhar Gopal Das, Gordon (Gordy) Haupt, Uday Bawa, David L. Evans, Tracy Metzger, Ian Moore and Anoop Bhatia. “We are shifting gears in our growth journey,” said Bhatia. “The announcement of the growth council aims to provide co-benefits to our customers with value-driven innovation in the fields of machine learning and natural language processing.” Nowigence is an innovative software as a service (“SaaS”) company, focused on developing and bringing to market Pluaris, its comprehensive, ready-to-use artificial intelligence platform. By integrating state-of-the-art data-processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to NOWG are available in the company’s newsroom at https://ibn.fm/NOWG